Literature DB >> 7751877

Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma.

Y Yan1, W C Chan, D D Weisenburger, J R Anderson, M A Bast, J M Vose, P J Bierman, J O Armitage.   

Abstract

PURPOSE: We studied the effect of morphology and extent of bone marrow (BM) infiltrate on the survival of patients with diffuse aggressive B-cell non-Hodgkin's lymphoma (NHL), along with clinical features. PATIENTS AND METHODS: Sixty adult patients with diffuse aggressive B-cell NHL and BM involvement at the time of presentation were studied. All patients were uniformly staged and treated with a curative high-dose chemotherapy regimen. BM involvement was assessed according to the cytology, pattern of infiltration, and extent of involvement, and was correlated with overall survival (OS) and failure-free survival (FFS).
RESULTS: Patients with BM involvement that consisted of > or = 50% large cells or BM involvement of > or = 70% had a poorer OS (P = .065 and P = .055, respectively). Those who presented with an infiltrate of less than 50% large cells and an international prognostic index (IPI) of < or = 3 had a significantly longer postrelapse survival time (P = .003). A diffuse or interstitial pattern of BM involvement was predictive of both poor OS and FFS (P = .008 and .009, respectively). Multivariate analysis indicated that only IPI (P = .0005) and pattern of BM infiltration (P = .009) were independent predictors of OS, and only the former was predictive of FFS (P = .03).
CONCLUSION: The IPI is predictive of OS and FFS, while BM involvement with a diffuse or interstitial pattern is associated with significantly poorer OS. Patients with BM infiltration that involved > or = 70% of the marrow or contained > or = 50% large cells had poor OS, but more patients need to be studied to determine the significance. Two parameters, IPI < or = 3 and BM large cells less than 50%, identify a group of patients with long-term survival after relapse.

Entities:  

Mesh:

Year:  1995        PMID: 7751877     DOI: 10.1200/JCO.1995.13.6.1336

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

Review 1.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

2.  Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).

Authors:  Dipti Talaulikar; Jane Esther Dahlstrom; Bruce Shadbolt; Amy Broomfield; Anne McDonald
Journal:  J Histochem Cytochem       Date:  2008-06-23       Impact factor: 2.479

3.  High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.

Authors:  Moo-Kon Song; Joo-Seop Chung; Je-Jung Lee; Deok-Hwan Yang; In-Suk Kim; Dong-Hoon Shin; Ho-Jin Shin
Journal:  Int J Hematol       Date:  2014-12-12       Impact factor: 2.490

4.  B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.

Authors:  Leo Zhang; Krystle Nomie; Hui Zhang; Taylor Bell; Lan Pham; Sabah Kadri; Jeremy Segal; Shaoying Li; Shouhao Zhou; David Santos; Shawana Richard; Shruti Sharma; Wendy Chen; Onyekachukwu Oriabure; Yang Liu; Shengjian Huang; Hui Guo; Zhihong Chen; Wenjing Tao; Carrie Li; Jack Wang; Bingliang Fang; Jacqueline Wang; Lei Li; Maria Badillo; Makhdum Ahmed; Selvi Thirumurthi; Steven Y Huang; Yiping Shao; Laura Lam; Qing Yi; Y Lynn Wang; Michael Wang
Journal:  Clin Cancer Res       Date:  2017-03-27       Impact factor: 12.531

5.  If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.

Authors:  Patrizia Mancuso; Angelica Calleri; Pierluigi Antoniotti; Jessica Quarna; Giancarlo Pruneri; Francesco Bertolini
Journal:  BMC Cancer       Date:  2010-11-24       Impact factor: 4.430

6.  Lack of utility of CD20 immunohistochemistry in staging bone marrow biopsies for diffuse large B-cell lymphoma.

Authors:  Daniel Baiyee; Roger Warnke; Yasodha Natkunam
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-03

7.  Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

Authors:  Yong Won Choi; Seong Hyun Jeong; Mi Sun Ahn; Hyun Woo Lee; Seok Yun Kang; Jin-Hyuk Choi; U Ram Jin; Joon Seong Park
Journal:  J Korean Med Sci       Date:  2014-11-04       Impact factor: 2.153

8.  Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.

Authors:  Jin-Hua Liang; Jin Sun; Li Wang; Lei Fan; Yao-Yu Chen; Xiao-Yan Qu; Tian-Nv Li; Jian-Yong Li; Wei Xu
Journal:  Oncotarget       Date:  2016-04-05

Review 9.  Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party.

Authors:  Yong Park; Byung Bae Park; Ji Yun Jeong; Wook Youn Kim; Seongsoo Jang; Bong Kyung Shin; Dong Soon Lee; Jae Ho Han; Chan-Jeoung Park; Cheolwon Suh; Insun Kim; Hyun-Sook Chi
Journal:  Korean J Intern Med       Date:  2016-11-01       Impact factor: 2.884

10.  Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement.

Authors:  Kil Chan Oh; Dae Young Zang
Journal:  Korean J Intern Med       Date:  2003-03       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.